2022-06-02 ペンシルベニア州立大学(PennState)
<関連情報>
- https://www.psu.edu/news/research/story/vaccines-have-90-efficacy-against-severe-covid-19-six-months/
- https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-022-07418-y
SARS-CoV-2ワクチンの感染、症候性、重症に対する有効性 COVID-19:系統的レビューとメタ解析 SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis
Paddy Ssentongo,Anna E. Ssentongo,Navya Voleti,Destin Groff,Ashley Sun,Djibril M. Ba,Jonathan Nunez,Leslie J. Parent,Vernon M. Chinchilli & Catharine I. Paules
BMC Infectious Diseases Published:07 May 2022
DOI:https://doi.org/10.1186/s12879-022-07418-y
Abstract
Background
The temporal evolution of SARS-CoV-2 vaccine efficacy and effectiveness (VE) against infection, symptomatic, and severe COVID-19 is incompletely defined. The temporal evolution of VE could be dependent on age, vaccine types, variants of the virus, and geographic region. We aimed to conduct a systematic review and meta-analysis of the duration of VE against SARS-CoV-2 infection, symptomatic COVID-19 and severe COVID-19.
Methods
MEDLINE, Scopus, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, the World Health Organization Global Literature on Coronavirus Disease, and CoronaCentral databases were searched and studies were selected. Independent reviewers selected randomized controlled trials and cohort studies with the outcome of interest. Independent reviewers extracted data, and assessed the risk of bias. Meta-analysis was performed with the DerSimonian-Laird random-effects model with Hartung-Knapp-Sidik-Jonkman variance correction. The GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach was used to assess certainty (quality) of the evidence. Primary outcomes included VE as a function of time against SARS-CoV-2 infection, symptomatic and severe COVID-19.
Results
Eighteen studies were included representing nearly 7 million individuals. VE against all SARS-CoV-2 infections declined from 83% in the first month after completion of the original vaccination series to 22% at 5 months or longer. Similarly, VE against symptomatic COVID-19 declined from 94% in the first month after vaccination to 64% by the fourth month. VE against severe COVID-19 for all ages was high overall, with the level being 90% (95% CI, 87–92%) at five months or longer after being fully vaccinated. VE against severe COVID-19 was lower in individuals ≥ 65 years and those who received Ad26.COV2.S.
Conclusions
VE against SARS-CoV-2 infection and symptomatic COVID-19 waned over time but protection remained high against severe COVID-19. These data can be used to inform public health decisions around the need for booster vaccination.
